Our laboratory has demonstrated SC tumors are more responsive than visceral tumors to trimAb immunotherapy (anti-DR5, anti-CD40, and anti-4-1BB) in multiple murine tumor models (2). This evidence concerns the gene TNFRSF10B and neoplasm.